Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

February 26-28, 2019
Hilton Tokyo Bay Hotel,
Tokyo, Japan

THE ONLY EVENT IN ASIA BRINGING TOGETHER SCIENCE, TECHNOLOGIES AND PARTNERS TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE MOLECULES TO MARKET

CALL FOR SPEAKERS

SUBMIT YOUR PROPOSAL BY AUGUST 30, 2018

Want to speak at AsiaTIDES?

  • Oligonucleotide Discovery Technologies and Oligo Design Strategies
  • Oligonucleotide Therapeutics: Preclinical and Clinical Development Strategies
  • Oligonucleotide Manufacturing, CMC and Analytical Case Studies & Technologies
  • Peptide Discovery Technologies and Peptide Design Strategies
  • Peptide Therapeutics: Preclinical and Clinical Development Strategies
  • Peptide Manufacturing, CMC and Analytical Case Studies & Technologies
  • Novel Drug Delivery Technologies with Applications for Oligonucleotides and Peptides
  • Messenger RNA (mRNA) Therapeutics
  • Peptide Vaccines, Peptide Cocktails and Peptide-based Immunotherapies
  • CRISPR/CAS for Gene Editing, Gene Therapy, Silencing and Therapeutics
  • Delivery of Macromolecular Therapeutics: Oligos, Peptides, CRISPR, mRNA
  • Regulatory Strategies & Considerations for Peptides and Oligonucleotides
  • Early Stage Company Showcase of Oligonucleotide and Peptide Companies

Access the Science, Technologies and Partners You Need to Grow Your Business

Accelerate Your Product to Market

Hear case studies, best practices and lessons learned from global oligonucleotide and peptide developers currently in phase 2/3 clinical trials. Ensure product approval by hearing regulatory guidance and roadmaps to successful IND/IMPD submissions from industry leaders.

Evaluate New Technologies and Services

Improve your process development, analytical and manufacturing efforts by meeting with 20+ global technology leaders in the exhibit hall. The exhibit hall also features peer-submitted posters that contain new and unpublished research from global scientists working across all phases of oligonucleotide and peptide development.

Meet Your Next Partner at AsiaTIDES

Connect with 300+ oligonucleotide and peptide leaders across Asia, Europe and North America during networking lunches, dinners and cocktail receptions.

TIDES Digital Week


Join us 17-20 September 2018 for TIDES: Oligonucleotide & Peptide Therapeutics Digital Week: 4 days packed with webinars to help you stay current on the latest industry news and developments. And, it's completely free! Plus, get the questions answers to your toughest questions from our speakers during live Q&As.

Interested in sponsorship opportunities? Partner your way to oligo and peptide therapeutic success by sponsoring TIDES: Oligonucleotide & Peptide Therapeutics Digital Week. Engage our digital oligo and peptide audience while generating leads, promoting your brand, and demonstrating your expertise.

To learn more about sponsorship opportunities, contact partners@knect365lifesciences.com or request sponsor details.

PARTNERING OPPORTUNITIES FOR ASIATIDES 2019

Meet

Meet face-to-face with top-notch researchers and executives from pharmaceutical and biotechnology companies

Showcase

Showcase your latest technology to our targeted audience of key decision-makers

Build

Build invaluable relationships and form new partnerships that give you a competitive advantage in the US, Europe and Asia-Pacific

Gain

Gain international exposure through our specialized marketing campaign

Network

Network with international players in the industry

Thank you to our AsiaTIDES 2018 Scientific Advisory Board

  • Hiroaki Suga, Ph.D., Professor of Chemistry, School of Science, University of Tokyo, Japan
  • Osamu Sato, Executive Director, R&D Planning Department, Daiichi Sankyo, Japan
  • Daisuke Takahashi, Ph.D., Senior Principal Researcher, Bio-functional Molecular Chemistry Group, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto. Co., Inc., Japan
  • Hideaki Sato, General Manager, Technical Support and Marketing, GeneDesign, Inc., Japan



  • Robert Hagopian, Director Business Development, PolyPeptide Laboratories, USA
  • Yasuhiro Hayashi, Ph.D., Chief Scientist, Drug Discovery Group, R&D Division, AnGes MG, Inc., Japan
  • Yusuke Kohno, Vice President, Jitsubo Co Limited, Japan
  • Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and CEO & Founder, OliX Pharmaceuticals, Korea
  • Shawn Lee, Ph.D., President and CEO, CPC Scientific, USA and China
  • Patrick Lu, Ph.D., Founder, President and CEO, Sirnaomics, Inc., USA
  • Michael McGinley, Manager- Core Products, Phenomenex, USA
  • Bruce Morimoto, Ph.D., Executive Director Applied Translational Medicine, Celerion, USA
  • El Djouhar Reka├», Head of Peptide Products Operation, PolyPeptide Group, Belgium
  • G. Susan Srivatsa, Ph.D., President, ElixinPharma, USA
  • Dmitry Samarsky, Ph.D., Chief Scientific Officer, Silence Therapeutics, USA
  • Mimoun Ayoub, Ph.D., Industry Expert